摘要
目的探讨盐酸美金刚联合多奈哌齐治疗中、重度阿尔茨海默病(AD)的临床疗效及安全性。方法将86例AD患者随机分为盐酸美金刚联合多奈哌齐组(实验组)和多奈哌齐组(对照组),在治疗前、治疗后24周末分别利用简易智能状态检查(MMSE)评分量表、AD评估量表-认知部分(ADAS-cog)、日常生活能力(ADL)量表和神经精神症状问卷(NPI)评估。结果实验组和对照组在治疗前后ADAS-cog、ADL和NPI及MMSE差异均有统计学意义(P<0.01),实验组的NPI评分变化高于对照组(P<0.05)。两组不良反应事件发生率差异无统计学意义(P>0.05)。结论实验组和对照组对AD认知功能均有改善,但前者对NPI的改善更明显,两组治疗均具有良好的安全性。
Objective To discuss the effects and security of memantine and donepezil in the treatment of moderate to severe Alzheimer’s disease（AD）. Methods Eighty-six AD patients were randomly divided into two groups, the obser-vation group was treated by memantine and donepezil, while the control group was treated by donepezil. The mini-mental state examination （MMSE）, ADAS-cog, ADL, NPI were used to evaluate the clinical effects before and after treatment 24 weeks. Results The scores of ADAS-cog,ADL,NPI and MMSE were great significant（P〈0.01） in two groups before and after the treatment, the changes of NPI scores in the observation group were significantly higher than in control group （P〈0.05）,but the adverse reaction of two groups had no significantly difference（P〉0.05）. Conclusion Both of the two groups have clinical effect on treatment of AD,but memantine and donepezil is better efficacy than donepezil in NPI, and they are all safe.
出处
《中国现代医生》
2014年第18期42-44,47,共4页
China Modern Doctor
基金
国家自然科学基金(81373703)
